GSK EBITDA 2010-2023 | GSK
GSK annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- GSK EBITDA for the quarter ending March 31, 2023 was $3.307B, a 29.69% decline year-over-year.
- GSK EBITDA for the twelve months ending March 31, 2023 was $9.216B, a 30.02% decline year-over-year.
- GSK 2022 annual EBITDA was $10.613B, a 24.46% increase from 2021.
- GSK 2021 annual EBITDA was $8.527B, a 34.47% decline from 2020.
- GSK 2020 annual EBITDA was $13.012B, a 9.63% increase from 2019.
GSK Annual EBITDA
(Millions of US $) |
| 2022 |
$10,613 |
| 2021 |
$8,527 |
| 2020 |
$13,012 |
| 2019 |
$11,869 |
| 2018 |
$9,796 |
| 2017 |
$7,744 |
| 2016 |
$5,925 |
| 2015 |
$18,275 |
| 2014 |
$8,756 |
| 2013 |
$12,606 |
| 2012 |
$13,437 |
| 2011 |
$15,216 |
| 2010 |
$9,052 |
| 2009 |
$15,183 |
GSK Quarterly EBITDA
(Millions of US $) |
| 2023-03-31 |
$3,307 |
| 2022-12-31 |
$1,396 |
| 2022-09-30 |
$2,425 |
| 2022-06-30 |
$2,089 |
| 2022-03-31 |
$4,703 |
| 2021-12-31 |
$1,179 |
| 2021-09-30 |
$4,013 |
| 2021-06-30 |
$3,276 |
| 2021-03-31 |
$2,832 |
| 2020-12-31 |
$4,922 |
| 2020-09-30 |
$3,179 |
| 2020-06-30 |
$2,083 |
| 2020-03-31 |
$2,828 |
| 2019-12-31 |
$2,405 |
| 2019-09-30 |
$3,177 |
| 2019-06-30 |
$2,886 |
| 2019-03-31 |
$3,401 |
| 2018-12-31 |
$2,323 |
| 2018-09-30 |
$3,096 |
| 2018-06-30 |
$1,311 |
| 2018-03-31 |
$3,067 |
| 2017-12-31 |
$439 |
| 2017-09-30 |
$3,396 |
| 2017-06-30 |
$1,378 |
| 2017-03-31 |
$2,532 |
| 2016-09-30 |
$2,014 |
| 2016-06-30 |
$360 |
| 2016-03-31 |
$1,835 |
| 2015-12-31 |
$13,767 |
| 2015-09-30 |
$3,349 |
| 2015-06-30 |
$61 |
| 2015-03-31 |
$1,167 |
| 2014-12-31 |
$1,061 |
| 2014-09-30 |
$1,983 |
| 2014-06-30 |
$2,401 |
| 2014-03-31 |
$2,747 |
| 2013-12-31 |
$3,037 |
| 2013-09-30 |
$3,862 |
| 2013-06-30 |
$2,988 |
| 2013-03-31 |
$3,037 |
| 2012-12-31 |
$4,093 |
| 2012-09-30 |
$3,274 |
| 2012-06-30 |
$3,016 |
| 2012-03-31 |
$3,379 |
| 2011-12-31 |
$4,525 |
| 2011-09-30 |
$4,033 |
| 2011-06-30 |
$3,546 |
| 2011-03-31 |
$2,960 |
| 2010-12-31 |
$617 |
| 2010-09-30 |
$3,967 |
| 2010-06-30 |
$-551 |
| 2010-03-31 |
$3,796 |
| 2009-12-31 |
$4,021 |
| 2009-09-30 |
$4,264 |
| 2009-06-30 |
$3,800 |
| 2009-03-31 |
$3,251 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$69.839B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
